Abstract
To explore whether antithrombotic medication may protect against cognitive decline, tests of verbal memory, attention, abstract reasoning, verbal fluency, and mental flexibility were administered to 405 men at risk of cardiovascular disease. These subjects were a subgroup of those who had been participating in a randomised double blind factorial trial of low dose aspirin (75 mg daily) and low intensity oral anticoagulation with warfarin (international normalised ratio of 1.5) at 35 general practices across the United Kingdom for at least five years, were at least 55 years old at trial entry, and had been randomly allocated to one of four groups: active warfarin and active aspirin, active warfarin and placebo aspirin, placebo warfarin and active aspirin, and double placebo. Verbal fluency and mental flexibility were significantly better in subjects taking antithrombotic medication than in subjects taking placebo. Aspirin may have contributed more than warfarin to any beneficial effect. These results provide tentative evidence that antithrombotic medication may protect cognitive function in men at risk of cardiovascular disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clarke R. J., Mayo G., Price P., FitzGerald G. A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991 Oct 17;325(16):1137–1141. doi: 10.1056/NEJM199110173251605. [DOI] [PubMed] [Google Scholar]
- Desmond D. W., Tatemichi T. K., Paik M., Stern Y. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol. 1993 Feb;50(2):162–166. doi: 10.1001/archneur.1993.00540020040015. [DOI] [PubMed] [Google Scholar]
- Gorkin L., Norvell N. K., Rosen R. C., Charles E., Shumaker S. A., McIntyre K. M., Capone R. J., Kostis J., Niaura R., Woods P. Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy. Am J Cardiol. 1993 May 1;71(12):1069–1073. doi: 10.1016/0002-9149(93)90575-w. [DOI] [PubMed] [Google Scholar]
- May F. E., Moore M. T., Stewart R. B., Hale W. E. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly. Gerontology. 1992;38(5):275–279. doi: 10.1159/000213340. [DOI] [PubMed] [Google Scholar]
- Meade T. W., Roderick P. J., Brennan P. J., Wilkes H. C., Kelleher C. C. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 1992 Jul 6;68(1):1–6. [PubMed] [Google Scholar]
- Meade T. W., Wilkes H. C., Stirling Y., Brennan P. J., Kelleher C., Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J. 1988 Aug;9(8):836–843. doi: 10.1093/oxfordjournals.eurheartj.a062576. [DOI] [PubMed] [Google Scholar]
- Meyer J. S., Rogers R. L., McClintic K., Mortel K. F., Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 Jun;37(6):549–555. doi: 10.1111/j.1532-5415.1989.tb05688.x. [DOI] [PubMed] [Google Scholar]
- Stürmer T., Glynn R. J., Field T. S., Taylor J. O., Hennekens C. H. Aspirin use and cognitive function in the elderly. Am J Epidemiol. 1996 Apr 1;143(7):683–691. doi: 10.1093/oxfordjournals.aje.a008801. [DOI] [PubMed] [Google Scholar]
- Taylor A. E., Saint-Cyr J. A., Lang A. E. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain. 1986 Oct;109(Pt 5):845–883. doi: 10.1093/brain/109.5.845. [DOI] [PubMed] [Google Scholar]
- Waldstein S. R., Manuck S. B., Ryan C. M., Muldoon M. F. Neuropsychological correlates of hypertension: review and methodologic considerations. Psychol Bull. 1991 Nov;110(3):451–468. doi: 10.1037/0033-2909.110.3.451. [DOI] [PubMed] [Google Scholar]